https://www.selleckchem.com/products/deg-77.html
nstrates the reliability of PSMA-PET/CT in the workup of PCa patients with BCR, and its worldwide feasibility.68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumour (NET) detection and localisation. However, the optimal peptide mass and radioactivity ranges for 68Ga-satoreotide trizoxetan have not yet been established. We therefore aimed to determine its optimal dosing regimen in patients with metastatic gastroenteropancreatic NETs in a prospec
Like
Comment
Share
